Microcap Ledger Fennec Pharmaceuticals Inc. $FENC
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Research Triangle Park, NC
- Fiscal year end
- December 31
- Shares outstanding
- 35,067,159 [10-Q 2026-08-13]
What the company doesAI summary of filing
Fennec Pharmaceuticals develops and commercializes pharmaceutical products, with PEDMARK (sodium thiosulfate injection) as its sole approved product in the United States for preventing cisplatin-induced ototoxicity in pediatric cancer patients. The company generates revenue from PEDMARK sales and is pursuing regulatory approval and commercialization of this product outside the United States. Fennec is a revenue-generating company that also engages in patent enforcement activities to protect its intellectual property rights against generic competitors. The company's business depends substantially on maintaining patent protection for PEDMARK and its ability to commercialize the product globally. [10-K 2026-03-27]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $32.98M | $2.17M | $2.43M | $41.25M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $44.64M | −$9.74B | −$12.47M | $36.79M | [10-K 2026-03-27] |
| FY ended Dec 2024 | $47.54M | −$436.00M | $26.98M | $26.63M | [10-K 2026-03-27] |
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-05 | 27,432,234 | [10-Q 2024-11-08] |
| 2025-03-24 | 27,594,008 | [10-K 2025-03-26] |
| 2025-05-09 | 27,618,743 | [10-Q 2025-05-14] |
| 2025-08-11 | 27,831,698 | [10-Q 2025-08-14] |
| 2025-11-10 | 28,116,829 | [10-Q 2025-11-13] |
| 2026-03-20 | 34,475,178 | [10-K 2026-03-27] |
| 2026-05-12 | 34,737,030 | [10-Q 2026-05-14] |
| 2026-08-11 | 35,067,159 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2023-11-09; declared effective 2023-12-15 [S-3 2023-11-09]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-30 | Sayad Pierre Sargis | grant | 168 | — | [4 2026-10-01] |
| 2026-09-30 | Evans Terry L | grant | 168 | — | [4 2026-10-01] |
| 2026-09-30 | Hackman Jeffrey S. | grant | 1,159 | — | [4 2026-10-01] |
| 2026-09-30 | Cioffi Christiana Marie | grant | 156 | — | [4 2026-10-01] |
| 2026-09-30 | Andrade Robert | grant | 1,703 | — | [4 2026-10-01] |
| 2026-09-15 | Brughera Marco Maria | exercise | 15,545 | $2.11 | [4 2026-09-16] |
| 2026-09-15 | Brughera Marco Maria | sell | 15,545 | $10.29 | [4 2026-09-16] |
| 2026-09-01 | Raykov Rosty | sell | 10,000 | $12.11 | [4 2026-09-01] |
| 2026-08-31 | Raykov Rosty | grant | 2,778 | — | [4 2026-09-01] |
| 2026-08-31 | Sayad Pierre Sargis | grant | 168 | — | [4 2026-08-31] |
| 2026-08-31 | Sayad Pierre Sargis | sell | 12,000 | $12.18 | [4 2026-08-31] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-17 | 8-K | Other events |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-10 | 8-K | Shareholder vote results |
| 2026-05-22 | 8-K | Other events |
| 2026-05-18 | 8-K | Director or officer change |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 10-Q | Quarterly report |
| 2026-05-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-04-28 | 8-K | Director or officer change |
Alerts for $FENC
Email me when Fennec Pharmaceuticals Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.